MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02466nam a22003617a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
240723s20242024 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1523-3774 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/s11926-024-01147-8 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
38568326 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
AA Amyloidosis: A Contemporary View. [Review] |
| 251 ## - Source |
|---|
| Source |
Current Rheumatology Reports. 2024 Apr 03 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Curr Rheumatol Rep. 2024 Apr 03 |
| 253 ## - Journal Name |
|---|
| Journal name |
Current rheumatology reports |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2024 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2024 Apr 03 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
aheadofprint |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Medline status |
Publisher |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2024-07-23 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
PURPOSE OF REVIEW: Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RECENT FINDINGS: The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents. The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed. Copyright © 2024. The Author(s). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Indexing |
Automated |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Internal Medicine Residency |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Georgetown University Hospital/MedStar Washington Hospital Center |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Doumas, Stavros |
| Institution Code |
MGUH |
| Program |
Internal Medicine Residency |
| Degree |
MD |
| 790 ## - Authors |
|---|
| All authors |
Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, Frangou E, Gul A |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1007/s11926-024-01147-8">https://dx.doi.org/10.1007/s11926-024-01147-8</a> |
| Public note |
https://dx.doi.org/10.1007/s11926-024-01147-8 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
